Postoperative interferon therapy after resection of hepatitis C virus-related hepatocellular carcinoma

Japanese Journal of Gastroenterology

Volumn 105, Issue 6, 2008, Pages 795-801

  Katagiri, Satoshi ^a   Tokushige, Katsutoshi ^a   Yamamoto, Masakazu ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; INDOCYANINE GREEN; METHOTREXATE; PEGINTERFERON ALPHA; THYMIDYLATE SYNTHASE; VIRUS RNA; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURGERY; CHRONIC HEPATITIS; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PARENCHYMA; MALE; OCCULT CANCER; POSTOPERATIVE CARE; TUMOR DIFFERENTIATION; ADJUVANT CHEMOTHERAPY; DRUG COMBINATION; LIVER RESECTION; LIVER TUMOR; MIDDLE AGED; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; DRUG THERAPY, COMBINATION; FEMALE; HEPATECTOMY; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 49049097582     PISSN: 04466586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Takenaka K, Yamamoto K, Taketomi A, et al: A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology 22;20-24:1995
2. Miyagawa S, Kawasaki S, Makuuchi M: Comparison of the characteristics of hepatocellular carcinoma between hapatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology 24;307-310:1996
3. Kumada T, Nakano S, Takeda I, et al: Patterns of reccurence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25;87-92:1997
4. Nishiguchi S, Kuroki T, Nakatani S, et al: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346;1051-1055:1995
5. Yoshida H, Shiratori Y, Moriyama M, et al: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hapatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131;174-181:1999
6. Ikeda K, Saitoh S, Arase Y, et al: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29;1124-1130:1999
7. Ikeda K, Arase Y, Saitoh S, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32;228-232:2000
8. Kubo S, Nishiguchi S, Hirohashi K, et al: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134;963-967:2001
9. Kubo S, Nishiguchi S, Hirohashi K, et al: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89;418-422:2002
10. Kubo S, Nishiguchi S, Hirohashi K, et al: Influence of previous interferon therapy on recurrence after resection of hapatitis C virus-related hepatocellular carcinoma. Jpn J Cancer Res 92;59-66:2001
11. Uenishi T, Kubo S, Hirohashi K, et al: Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 24;404-412:2002
12. Hung CH, Lee CM, Lu SN, et al: Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 13;409-414:2006
13. Toyoda H, Kumada T, Honda T, et al: Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J Gastroenterol Hepatol 16;1131-1137:2001
14. Balart LA, Perrillo R, Roddenberry J, et al: Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment. Gastroenterology 104;1472-1477:1993
15. Shiratori Y, Shiina S, Teratani T, et al: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138;299-306:2003
16. Guadagni F, Schlom J, Johnston WW, et al: Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 81;502-512:1989
17. Kimchi A: Cytokine triggered molecular pathways that control cell cycle arrest. J Cell Biochem 50;1-9:1992
18. Grander D, Xu B, Einhorn S: Cytotoxic effect of interferon on primary malignant tumour cells. Studies in various malignancies. Eur J Cancer 29 A;1940-1943:1993
19. Ortaldo JR, Mantovani A, Hobbs D, et al: Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer 31;285-289:1983
20. Uno K, Shimizu S, Ido M, et al: Direct and indirect effects of interferon on in vivo murine tumor cell growth. Cancer Res 45;1320-1327:1985
21. Brinkmann V, Geiger T, Alkan S, et al: Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med 178;1655-1663:1993
22. Wang L, Tang ZY, Qin LX, et al: High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32;43-48:2000
23. Lai CL, Lau JY, Wu PC, et al: Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 17;389-394:1993
24. Llovet JM, Sala M, Castells L, et al: Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31;54-58:2000
25. Schwartz EL, Hoffman M, O'Connor CJ, et al: Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun 182;1232-1239:1992
26. Horowitz RW, Heerdt BG, Hu X, et al: Combination therapy with 5-fluorouracil and IFN-alpha 2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells. Clin Cancer Res 3;1317-1322:1997
27. Yamamoto T, Nagano H, Sakon M, et al: Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. Clin Cancer Res 10;7884-7895:2004
28. Patt YZ, Yoffe B, Charnsangavej C, et al: Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer 72;2574-2582:1993
29. Chung YH, Song IH, Song BC, et al: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 88;1986-1991:2000
30. Urabe T, Kaneko S, Matsushita E, et al: Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 55;39-47:1998
31. Leung TW, Patt YZ, Lau WY, et al: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5;1676-1681:1999
32. Sakon M, Nagano H, Dono K, et al: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94;435-442:2002